Ganciclovir Market Size & Growth Analysis to 2030

The global ganciclovir market size is anticipated to register a significant CAGR of 6.1% and estimated to reach at USD 627 million by 2027. The rising prevalence of cytomegalovirus (CMV) retinitis in immunocompromised patients worldwide primarily drives the ganciclovir market growth. Additionally, the high mortality rate associated with CMV pneumonitis infection in patients undergoing solid organ transplantation further accentuates the market growth in the region.

Ganciclovir is basically an antiviral drug which is a synthetic nucleoside analogue of 2′-deoxyguanosine which is involved in the inhibition of replication of herpes virus by getting incorporated in the viral DNA. It is available as a lyophilized powder for the solution to be injected in the concentration of 50 mg/1mL and capsules of dose strength of 500mg and 250 mg accordingly.

Market Drivers:

Increasing Incidence of Viral Infections: Ganciclovir is an antiviral medication primarily used for the treatment and prevention of infections caused by the herpes virus, including cytomegalovirus (CMV) infections. The rising incidence of viral infections, particularly among immunocompromised individuals such as transplant recipients and people with HIV/AIDS, drives the demand for ganciclovir.

Organ Transplantation and Immunosuppressive Therapy: Organ transplantation often requires the use of immunosuppressive medications to prevent organ rejection. However, these medications weaken the immune system, making patients more susceptible to viral infections, including CMV. Ganciclovir is commonly used as a prophylactic or therapeutic agent in organ transplant recipients, driving its demand in this patient population.

HIV/AIDS Treatment: Individuals with HIV/AIDS are prone to opportunistic infections, including CMV retinitis, a severe viral infection of the eye. Ganciclovir is an essential treatment option for CMV retinitis in HIV/AIDS patients, contributing to the demand for the drug in this specific indication.

Ophthalmic Applications: Ganciclovir is also used in ophthalmology for the treatment of CMV retinitis and other viral infections of the eye. The prevalence of CMV retinitis and the need for effective treatment options in ophthalmic practice drive the demand for ganciclovir in this field.

Research and Development: Ongoing research and development activities aimed at exploring new applications of ganciclovir, improving its efficacy, and developing novel formulations contribute to market growth. The development of extended-release formulations, combination therapies, and alternative delivery methods can expand the market for ganciclovir.

Government Initiatives and Healthcare Policies: Government initiatives focused on improving healthcare infrastructure, increasing access to antiviral medications, and preventing viral infections can impact the ganciclovir market. Healthcare policies that emphasize the use of ganciclovir in specific indications, such as CMV prophylaxis in transplant recipients, can drive market growth.

Pharmaceutical Industry Collaborations: Collaborations between pharmaceutical companies, research institutions, and healthcare organizations play a role in driving the ganciclovir market. Partnerships aimed at conducting clinical trials, expanding the drug’s indications, or improving its formulation can contribute to market growth.

Market Outlook:

Market Insights:

Cytomegalovirus (CMV) retinitis is representing the largest market share in the clinical application segment for ganciclovir market. As per the latest research citings provided by the World Health Organization (WHO), approximately 40% of the people suffering from AIDS worldwide develop CMV retinitis during the later stage of their lives. The effective diagnosis of CMV retinitis can be performed with CD8+ T-lymphocyte count and ophthalmic screening frequency is based on CD4 count etc. It is basically the inflammation of the retina of the eye which if not adequately treated may lead to permanent blindness. Cytomegalovirus (CMV) pneumonitis is expected to be recording comfortable market growth during the forecast period. Patients who have undergone bone marrow transplants or solid organ transplants are at a greater risk of acquiring CMV pneumonitis. The incidence rate of the disease is 35% after allogeneic transplantation and 6% after autologous transplantation respectively.

To know more about the study, request a report sample

Hospital pharmacy is presently dominating the distribution channel segment for ganciclovir market. Judicious use of ganciclovir is imperative as it possesses teratogenicity properties, hence drug compounding needs to be done under the supervision of a trained hospital pharmacist. Retail pharmacies are gaining huge demand in the developing regions of the world primarily due to proactive initiatives by government healthcare authorities to provide subsidized antiviral drugs in retail pharmacies at affordable prices and ability to cater medicinal requirements of patients residing in remote locations.

The Ganciclovir comprehensive study offers an in-depth analysis of industry trends, market size, competitive analysis, and market forecast – 2020 to 2027. Research Corridor report provides detailed premium insight into the global market and reveals the potential revenue streams, commercial prospects, market drivers, challenges, opportunities, issues, and events affecting the industry. In addition, the report has a dedicated section covering market forecasts and analysis for leading geographies, profiles of major companies operating in the market and expert opinion obtained from interviews with industry executives and experts from prominent companies.

Historical & Forecast Period

• 2018-19 – Historical Year
• 2020 – Base Year
• 2021-2027 – Forecast Period

Market Segmentation:

By Clinical Application:

• Cytomegalovirus (CMV) Retinitis
• Cytomegalovirus (CMV) Pneumonitis
• Others

By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Others

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Geographic Coverage:

North America is currently leading the geography segment for the ganciclovir market. The rising prevalence of cytomegalovirus retinitis infection in immunocompromised patients primarily drives the ganciclovir market growth in the region. As per the statistics provided by the Center for Disease Control and Prevention (CDC), approximately 1 in 3 children by age 5 are already infected with cytomegalovirus in the United States. Furthermore, affordable reimbursement scenarios associated with the use of ganciclovir drug formulation further consolidate the market growth in the region. Europe is the second-largest regional segment in the ganciclovir market, primarily due to the rising prevalence of cytomegalovirus (CMV) pneumonitis in patients who have recently received a solid organ or bone marrow transplant in the region. Asia Pacific is anticipated to be the fastest-growing regional segment for the ganciclovir market owing to the rising prevalence of CMV infection in people suffering from AIDS and the flourishing generic drugs market.

Market Competition Assessment:

Key players operating in the global ganciclovir market are Thea Pharmaceuticals, F.Hoffman La Roche, Bausch & Lomb, Sandoz, Inc., and Fresenius Kabi. Companies are exploring markets by expansion, new investment, the introduction of new services, and collaboration as their preferred strategies. Players are exploring new geography through expansion and acquisition to gain a competitive advantage through joint synergy.

List of Key Companies:

• Thea Pharmaceuticals
• Hoffman La Roche
• Bausch & Lomb
• Sandoz, Inc.
• Sun Pharmaceutical Industries Ltd.
• Fresenius Kabi
• Teva Pharmaceutical Industries Ltd.
• Wuhan Hualong Bio-Pharmaceutical
• Par Pharmaceutical, Inc.
• Lafedar

Key Questions Answered by Ganciclovir Market Report:

• Global Ganciclovir market forecasts from 2021-2027
• Regional Ganciclovir market forecasts from 2021-2027 covering Asia-Pacific, North America, Europe, Middle East and Africa, and Latin America
• Country-level forecasts from 2021-2027 covering 15 major countries from the aforementioned regions
• Ganciclovir submarket forecasts from 2021-2027 covering the market by clinical application, by distribution channel, and geography
• Various industry models such as SWOT analysis, Value Chain Analysis pertaining to the Ganciclovir market
• Analysis of the key factors driving and restraining the growth of the global, regional and country-level Ganciclovir markets from 2021-2027
• Competitive Landscape and market positioning of top 10 players operating in the Ganciclovir market